1,147 results on '"Carraway, Hetty E."'
Search Results
2. Risk Prediction for Clonal Cytopenia: Multicenter Real-World Evidence.
3. Clinical and molecular characteristics of extramedullary acute myeloid leukemias
4. Non-canonical FLT3 alterations reveal novel germline FLT3 variants leading to somatic gene rescue mutations
5. Treatment of Relapsed Acute Lymphocytic Leukemia in Adult Patients
6. JAK2 p.R564 germ line variants associated with hereditary thrombocythemia and hematologic neoplasms
7. Contemporary Approach to the Diagnosis and Classification of Myelodysplastic Neoplasms/Syndromes—Recommendations From the International Consortium for Myelodysplastic Neoplasms/Syndromes (MDS [icMDS])
8. Data-driven, harmonised classification system for myelodysplastic syndromes: a consensus paper from the International Consortium for Myelodysplastic Syndromes
9. Molecular patterns identify distinct subclasses of myeloid neoplasia
10. Leukemia relapse via genetic immune escape after allogeneic hematopoietic cell transplantation
11. Reducing clinical trial eligibility barriers for patients with MDS: an icMDS position statement
12. Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS)
13. Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts
14. Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1st International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS)
15. Pattern of somatic mutation changes after allogeneic hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes
16. Recent progress in acute leukemia and myelodysplasia
17. Mutation profiles and outcomes of patients with acute myeloid leukemia with autoimmune disease.
18. Covalent-103: A phase 1, open-label, dose-escalation and expansion study of BMF-500, an oral covalent FLT3 inhibitor, in adults with acute leukemia (AL).
19. Outcomes of blast-phase MPN and JAK2, MPL, and CALRmutated de novo AML: A propensity score-adjusted cohort study.
20. Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms
21. Machine learning integrates genomic signatures for subclassification beyond primary and secondary acute myeloid leukemia
22. Phase 1 study of the histone deacetylase inhibitor entinostat plus clofarabine for poor-risk Philadelphia chromosome-negative (newly diagnosed older adults or adults with relapsed refractory disease) acute lymphoblastic leukemia or biphenotypic leukemia
23. Current and emerging strategies for management of myelodysplastic syndromes
24. Implication of PIGA genotype on erythrocytes phenotype in Paroxysmal Nocturnal Hemoglobinuria
25. Myeloid neoplasms with germline predisposition: Practical considerations and complications in the search for new susceptibility loci
26. Advances in non-intensive chemotherapy treatment options for adults diagnosed with acute myeloid leukemia
27. Toward a more patient‐centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS)
28. Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes
29. Author Correction: Molecular patterns identify distinct subclasses of myeloid neoplasia
30. Leukemia evolving from paroxysmal nocturnal hemoglobinuria
31. The novel autophagy inhibitor ROC-325 augments the antileukemic activity of azacitidine
32. Significance of the Apoptotic Regulators BAX, BCL2, BCL- XL and MCL1 in Newly Diagnosed AML
33. POSTER: AML-370 Phase IB OMNIVERSE Trial: Safety and Tolerability of Oral Azacitidine (Oral-AZA) in Combination With Venetoclax (VEN) for Treatment of Acute Myeloid Leukemia (AML)
34. AML-370 Phase IB OMNIVERSE Trial: Safety and Tolerability of Oral Azacitidine (Oral-AZA) in Combination With Venetoclax (VEN) for Treatment of Acute Myeloid Leukemia (AML)
35. Timed sequential therapy for acute myelogenous leukemia: Results of a retrospective study of 301 patients and review of the literature
36. Novel therapeutic strategies to target leukemic cells that hijack compartmentalized continuous hematopoietic stem cell niches
37. Author Correction: Activation of SIRT6 by DNA hypomethylating agents and clinical consequences on combination therapy in leukemia
38. Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes
39. Activation of SIRT6 by DNA hypomethylating agents and clinical consequences on combination therapy in leukemia
40. Influence of Killer Immunoglobulin-Like Receptors and Somatic Mutations on Transplant Outcomes in Acute Myeloid Leukemia
41. Updates in classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium of MDS (icMDS)
42. An Agenda to Advance Research in Myelodysplastic Syndromes: A TOP 10 Priority List From the First International Workshop in MDS
43. Overview of the Management of Higher-Risk Myelodysplastic Syndromes
44. Patterns of Diagnostic Evaluation and Determinants of Treatment in Older Patients With Non-transfusion Dependent Myelodysplastic Syndromes
45. Validation of the Molecular International Prognostic Scoring System in patients with myelodysplastic syndromes
46. Leukemia relapse via genetic immune escape after allogeneic hematopoietic cell transplantation
47. Supplemental Data from A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia
48. Supplements from IDH1/2 Mutations Sensitize Acute Myeloid Leukemia to PARP Inhibition and This Is Reversed by IDH1/2-Mutant Inhibitors
49. Supplemental Figures and Tables from A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic Leukemia
50. Data from Progressive Chromatin Repression and Promoter Methylation of CTNNA1 Associated with Advanced Myeloid Malignancies
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.